Pfizer Inc. (PFE) shares hit new 52-week high after positive results of Covid-19 vaccine
Pfizer says its experimental coronavirus vaccine more than 90 percent effective in trials
Staff or Guest writer for The Dog of Wall Street.
2020-11-09 12:10

Pfizer Inc. (PFE) on Monday announced that its experimental coronavirus vaccine achieved more than 90 percent effectiveness in treating the infected patients, sending its share up more than 8 percent this morning.

The announcement marks a major success in fight against the Covid-19, which has killed millions of people and disrupted many businesses and economies around the world. Pfizer and its German partner BioNTech SE (BNTX) are among the very few pharmaceutical companies to announce a successful data from a mass-scale trial of a coronavirus drug. 

PFE and BNTX said no serious side effect was observed during the trials. The two companies expect to seek immediate emergency authorization of the vaccine from the U.S. Food and Drug Administration (FDA).

Pfizer’s CEO Albert Bourla said in a statement “we are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

There are still some unanswered questions related to the vaccine, such as the availability of the drug in the United States and other countries after approval, as well as how long the drug will offer protection against the virus. 

Republican Party’s Presidential candidate Donald Trump also welcomed the news by tweeting "STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!"

Shares of both Pfizer Inc. (NYSE: PFE) and BioNTech (NASDAQ: BNTX) hit new 52-week high of $41.95 and $115.00, respectively, in the early trading Monday following the news.

Pfizer shares have been on a roller coaster ride since the start of the pandemic. PFE share price touched a low of around $28 in March. However, the stock managed to recover most of its lost value in the subsequent months. Overall, the stock has gained nearly 3 percent on year-to-date basis, including today’s surge. 

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Published On
2020-11-09 12:10

About the Author
Staff or Guest writer for The Dog of Wall Street.

Analyst Ratings
Target Price $84.25
# of Analysts 9
Last updated 2020-11-25

The COVID-19 vaccine market will not be a winner-takes-all
The US government has selected three vaccine candidates to fund their Phase 3 trials through Operation Warp Speed.
By Alcides | 1 year ago

Pfizer and BioNTech Granted FDA Fast Track Designation for COVID-19 vaccines
Pfizer and BioNTech were granted fast track designation by the FDA for two of the companies’ four vaccine candidates against the coronavirus.
By Staff | 1 year ago

What the Omicron Variant Means for Stocks
Investors woke up to a bloody day on the markets on Black Friday, and it wasn’t because Wall Street was having a sale on stocks.
By Mike Sakuraba | 3 days ago

2 Stocks on sale for Black Friday
Thanksgiving is a wonderful time of year for family, friends, and good food. It has also become the precursor to Black Friday, the biggest retail week of the year.
By Mike Sakuraba | 6 days ago

Is Rivian a Buy?
If anyone tells you that IPOs are mini bubbles and volatile to invest in, you should probably believe them.
By Mike Sakuraba | 1 week ago

Is it safe to buy AliBaba stock yet?
Over the past few months I have checked in a few times on Chinese tech giant AliBaba (NYSE:BABA).
By Mike Sakuraba | 1 week ago